HLA-C and neoplasm: Since they could directly recognize tumor cells in the absence of MHC and had low alloreactivity, allogeneic NK cells or even NK cell line hold important promise to carry a CAR for the development of “off the shelf” cancer immunotherapy (Figure 2C).